BP11125 PLGA 65:35, Lauryl Ester Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa

PLGA 65:35, Lauryl Ester Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Description

PLGA 65:35, Lauryl Ester Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa is a copolymer composed of a 65:35 lactide-to-glycolide ratio with lauryl ester end-capping, which affects its hydrophobicity and degradation profile. The defined intrinsic viscosity and molecular weight allow for controlled chain scission, making this biopolymer suitable for biomedical applications that require precise drug release and tissue scaffold performance.

PLGA 65:35, Lauryl Ester Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Applications

1.         Healthcare Applications
   - Used as a matrix in controlled drug delivery systems to achieve precise release profiles by leveraging predictable biodegradation.
   - Applied as a scaffold material in tissue engineering to support cell growth through consistent degradation behaviour.

2.         Industrial Applications
   - Utilised as an encapsulating agent in bioresorbable sensor devices to mitigate long-term residue by leveraging the polymer's tailored degradation rate.

PLGA 65:35, Lauryl Ester Terminated, IV: 0.55–0.65 dl/g, Mw: 70–88 kDa Packing

The powder is packaged in moisture barrier bags and sealed aluminium containers to prevent exposure to humidity and mechanical stress. Packaging incorporates anti-static measures and tamper-evident seals, ensuring the product maintains its defined molecular weight and viscosity during storage and transit. Storage should be in a cool, dry area. Custom packaging options are offered for bulk shipments and specialised storage requirements.

Additional Information

Biodegradable polymers like PLGA are widely studied for their hydrolytic degradation properties, which are critical in determining drug release rates and scaffold resorption in biomedical applications. The controlled polymer chain structure and end-capping modifications enable tailored degradation profiles that adapt to specific therapeutic needs.

Understanding the correlation between molecular weight, intrinsic viscosity, and degradation kinetics is essential for optimising biomedical devices. These parameters are carefully adjusted and monitored during synthesis to achieve reproducible performance, ensuring that the material meets rigorous standards for clinical and industrial use.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.